<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187264</url>
  </required_header>
  <id_info>
    <org_study_id>7557/PG/2Trg/07</org_study_id>
    <nct_id>NCT01187264</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study to Compare the Efficacy and Safety of Methotrexate in Plaque Type Psoriasis</brief_title>
  <official_title>Efficacy and Safety of Methotrexate in 2 Fixed Doses of 10mg or 25mg Orally Once Weekly in Patients With Severe Plaque Type Psoriasis: a Prospective, Randomized, Double Blind, Dose Ranging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators intend to compare the efficacy and safety of two fixed doses
      of once weekly oral methotrexate in a prospective randomized double blind manner in patients
      with severe plaque type psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in Psoriasis Area and Severity Index (PASI) score between two groups from baseline to 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to achieve PASI 75</measure>
    <time_frame>12 weeks or earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients achieving PASI 90 and 100</measure>
    <time_frame>12 weeks or earlier</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>methotrexate 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral methotrexate 10 mg once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methotrexate 25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral methotrexate 25 mg once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75</description>
    <arm_group_label>methotrexate 10 mg</arm_group_label>
    <arm_group_label>methotrexate 25mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with plaque-type psoriasis having more than 10% body surface area involvement
             (severe psoriasis).20

          -  Patients of either sex with age between 18-65 years.

          -  Females who were postmenopausal or tubectomised or have completed their family size
             and are willing to maintain contraception 1 month before, during and 1 month after
             completion/stopping of treatment and negative pregnancy test 2 weeks before starting
             of treatment and at day 2 or 3 of a normal menstrual cycle.

          -  Males who were willing to maintain contraception during and 3 months after
             completion/stopping of treatment.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Any abnormalities in renal function, cardiovascular disease, respiratory disease or
             neuropsychiatric illness.

          -  Significant abnormalities in liver function (serum bilirubin, AST, ALT, and ALP &gt;1.5
             times the upper limit of normal), viral hepatitis or cirrhosis.

          -  history of excessive alcohol consumption.

          -  Severe anemia, leucopenia or thrombocytopenia.

          -  Active infectious disease or immune system deficiency including AIDS.

          -  history of intolerance/hypersensitivity to methotrexate.

          -  history of phototherapy in past 6 months.

          -  Patients who had received any systemic treatment for psoriasis in the past 4 weeks and
             topical treatment in the past 2 weeks.

          -  Body mass index (BMI) &gt; 30 kg/m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C V KRISHNA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Postgraduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SUNIL DOGRA, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Postgraduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Postgraduate Institute of Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <state>U.T</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2010</study_first_posted>
  <last_update_submitted>August 24, 2010</last_update_submitted>
  <last_update_submitted_qc>August 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr C Vijay Krishna</name_title>
    <organization>postgraduate institute of medical education and research</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

